Clinical Trials Browser

Interventional × Leukemia × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all

Leukemia, Leukemia-Lymphoma, Adult T-Cell

NCT00077922 2018-01-23

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Phase 2 Completed

15 enrolled 10 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00002765 2015-04-29

Immunotoxin in Treating Patients With Leukemia or Lymphoma

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Immunotoxin in Treating Patients With Leukemia or Lymphoma